- Report
- March 2024
- 188 Pages
Global
From €3277EUR$3,374USD£2,827GBP
€3641EUR$3,749USD£3,141GBP
- Report
- January 2024
- 200 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Report
- February 2024
- 204 Pages
Global
From €3497EUR$3,600USD£3,016GBP
- Drug Pipelines
- April 2024
- 230 Pages
Global
From €2914EUR$3,000USD£2,514GBP
- Clinical Trials
- January 2024
- 100 Pages
Global
From €1943EUR$2,000USD£1,676GBP
The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite.
GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance.
Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more